Effectiveness of zinc supplementation on the possibility of recurrence of anxiety and depression in opioid dependent patients

Investigating the effectiveness of zinc supplementation on the possibility of relapse of anxiety and depression in opioid dependent patients under methadone maintenance treatment.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160417027437N3

Enrollment

Registered

2023-06-18

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients dependent on opioids. Opioid related disorders

Interventions

Intervention 1: Intervention group: In addition to methadone as the main treatment, patients in the intervention group will receive 220 mg zinc sulfate capsules every other day for three months. The d

Eligibility

Sex/Gender

All

Age

18 Years to 60 Months

Inclusion criteria

Inclusion criteria: Age 18 to 60 years Diagnosis of substance abuse disorder based on DSM-V diagnostic criteria Receiving methadone as the only treatment protocol

Exclusion criteria

Exclusion criteria: History of allergy to compounds containing zinc The use of compounds containing zinc and other medicinal supplements before intervention and study Having harmful thoughts to yourself and others

Design outcomes

Primary

Measure	Time frame
Anxiety. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Spielberger questionnaire.;Depression. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Beck depression questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Ali Moghadam Sadegh

Ahvaz University of Medical Sciences

moghaddam.a@ajums.ac.ir+98 61 3374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026